This supplement highlights how the power of choice is transforming AAA treatment in Europe. It also underscores the impact that EndoVascular Aneurysm Sealing (EVAS) has had on AAA treatment, and shows why the new Nellix device has the potential to become a workhorse device with promising results when treating patients within the instructions for use. It additionally explores the use of EVAS in iliac artery aneurysms, and presents an update on the EVAS FORWARD Global Registry, showing continued positive clinical outcomes with Nellix in an all-comer patient population.
[pdfviewer width=”100%” height=”940px” beta=”true”]https://vascularnews.com/wp-content/uploads/sites/7/2016/07/VN_Endologix-supplement-Jun2016-WEB.pdf[/pdfviewer]
